CA2506231A1 - Compositions destinees au traitement et/ou a la prevention de maladies caracterisees par la presence d'ions metalliques - Google Patents

Compositions destinees au traitement et/ou a la prevention de maladies caracterisees par la presence d'ions metalliques Download PDF

Info

Publication number
CA2506231A1
CA2506231A1 CA002506231A CA2506231A CA2506231A1 CA 2506231 A1 CA2506231 A1 CA 2506231A1 CA 002506231 A CA002506231 A CA 002506231A CA 2506231 A CA2506231 A CA 2506231A CA 2506231 A1 CA2506231 A1 CA 2506231A1
Authority
CA
Canada
Prior art keywords
compound
independently
atom
composition
carbon atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002506231A
Other languages
English (en)
Inventor
Orrie Friedman
Ivan Correia
Toby Sommer
David Alan Kew
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GrenPharma LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2506231A1 publication Critical patent/CA2506231A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

D'une manière générale, l'invention concerne le traitement et/ou la prévention de la maladie d'Alzheimer, d'autres maladies neurodégénératives et/ou de maladies caractérisées par la présence de certains ions métalliques à l'aide de certaines compositions contenant des composés organosiliciés. Une composition selon l'invention peut être administrée à un mammifère, tel qu'un être humain. Dans certains cas, cette composition peut comprendre un silanol, un silandiol, un silantriol ou un organosilane cyclique et/ou former un silanol, un silandiol ou un silantriol lorsqu'elle est exposée à des conditions physiologiques, telles que celles qui se manifestent dans le sang, dans l'estomac et/ou dans le tractus gastro-intestinal ou dans le cerveau ou un autre organe. Dans certains cas, le composé organosilicié peut être lié à une fraction pouvant être transportée dans le cerveau à travers la barrière hémato-encéphalique, par exemple, un acide aminé, un peptide, une protéine, un virus, etc. Le composé organosilicié peut également être étiqueté (par exemple, par fluorescence ou radioamarqué) dans certains cas. Dans certains modes de réalisation, une composition ou une partie de celle-ci peut séquestrer de l'aluminium ou d'autres ions, par exemple, par liaison électrostatique avec des ions aluminium. Cette composition peut également présenter d'autres fonctionnalités, telles que des amines, certaines fractions alkyle et/ou aryle (notamment des alkyles et/ou des aryles substitués) ou des fractions hydrophobes, par exemple, pour faciliter le transport du composé organosilicié à travers la barrière hémato-encéphalique.
CA002506231A 2002-11-18 2003-11-18 Compositions destinees au traitement et/ou a la prevention de maladies caracterisees par la presence d'ions metalliques Abandoned CA2506231A1 (fr)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US42720102P 2002-11-18 2002-11-18
US42710402P 2002-11-18 2002-11-18
US42720302P 2002-11-18 2002-11-18
US42710502P 2002-11-18 2002-11-18
US60/427,105 2002-11-18
US60/427,203 2002-11-18
US60/427,104 2002-11-18
US60/427,201 2002-11-18
US45634503P 2003-03-20 2003-03-20
US60/456,345 2003-03-20
USPCT/US03/36749 2003-11-17
US0336749 2003-11-17
PCT/US2003/037037 WO2004045552A2 (fr) 2002-11-18 2003-11-18 Compositions destinees au traitement et/ou a la prevention de maladies caracterisees par la presence d'ions metalliques

Publications (1)

Publication Number Publication Date
CA2506231A1 true CA2506231A1 (fr) 2004-06-03

Family

ID=34382290

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002506231A Abandoned CA2506231A1 (fr) 2002-11-18 2003-11-18 Compositions destinees au traitement et/ou a la prevention de maladies caracterisees par la presence d'ions metalliques

Country Status (5)

Country Link
JP (1) JP2006526567A (fr)
AU (1) AU2003298673A1 (fr)
CA (1) CA2506231A1 (fr)
MX (1) MXPA05005286A (fr)
WO (1) WO2004045552A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595308B2 (en) 2002-11-18 2009-09-29 Grenpharma Llc Compositions for treating and/or preventing diseases characterized by the presence of metal ions
WO2006028491A1 (fr) * 2004-02-13 2006-03-16 University Of Florida Biocides a base de silanes et siloxanes a terminaison silanol
US7960576B2 (en) 2004-08-13 2011-06-14 Momentive Performance Materials Inc. Diol-derived organofunctional silane and compositions containing same
US7928258B2 (en) 2004-08-20 2011-04-19 Momentive Performance Materials Inc. Cyclic diol-derived blocked mercaptofunctional silane compositions
WO2006047477A1 (fr) * 2004-10-22 2006-05-04 Grenpharama Llc Compositions destinees a traiter et / ou prevenir des maladies caracterisees par la presence d'ions metalliques
US7504456B2 (en) 2006-02-21 2009-03-17 Momentive Performance Materials Inc. Rubber composition containing organofunctional silane
US7919650B2 (en) 2006-02-21 2011-04-05 Momentive Performance Materials Inc. Organofunctional silanes and their mixtures
US7718819B2 (en) 2006-02-21 2010-05-18 Momentive Performance Materials Inc. Process for making organofunctional silanes and mixtures thereof
US7510670B2 (en) 2006-02-21 2009-03-31 Momentive Performance Materials Inc. Free flowing filler composition based on organofunctional silane
US8097744B2 (en) 2006-08-14 2012-01-17 Momentive Performance Materials Inc. Free flowing filler composition comprising mercapto-functional silane
US8008519B2 (en) 2006-08-14 2011-08-30 Momentive Performance Materials Inc. Process for making mercapto-functional silane
US8026108B1 (en) * 2006-10-19 2011-09-27 The University Of Central Florida Research Foundation, Inc. Detection of biotargets using bioreceptor functionalized nanoparticles
US7816435B2 (en) 2007-10-31 2010-10-19 Momentive Performance Materials Inc. Halo-functional silane, process for its preparation, rubber composition containing same and articles manufactured therefrom

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4039666A (en) * 1975-12-15 1977-08-02 Dow Corning Corporation Anticonvulsant phenylsilanes
US5384312A (en) * 1987-05-08 1995-01-24 Merrell Dow Pharmaceuticals Inc. Substituted silyl alkylene amines
WO1993001819A1 (fr) * 1991-07-15 1993-02-04 Ethyl Corporation Utilisation de composes a base de silicium dans la prevention de lesions traumatiques
US5523295A (en) * 1994-07-06 1996-06-04 Brandeis University Method for treating and preventing alzheimer's disease
FR2725208B1 (fr) * 1994-09-30 1996-11-29 Exsymol Sa Procede de preparation de composes de silicium biologiquement actifs sous forme concentree
US5854215A (en) * 1995-03-14 1998-12-29 Praecis Pharmaceuticals Incorporated Modulators of β-amyloid peptide aggregation
JPH10101569A (ja) * 1996-10-01 1998-04-21 Eisai Co Ltd 制酸剤
US5859277A (en) * 1997-06-25 1999-01-12 Wisconsin Alumni Research Foundation Silicon-containing solid support linker

Also Published As

Publication number Publication date
MXPA05005286A (es) 2006-02-22
WO2004045552A2 (fr) 2004-06-03
AU2003298673A1 (en) 2004-06-15
JP2006526567A (ja) 2006-11-24
WO2004045552A3 (fr) 2005-08-18

Similar Documents

Publication Publication Date Title
Zhang et al. α-Lipoic acid improves abnormal behavior by mitigation of oxidative stress, inflammation, ferroptosis, and tauopathy in P301S Tau transgenic mice
CA2506231A1 (fr) Compositions destinees au traitement et/ou a la prevention de maladies caracterisees par la presence d'ions metalliques
EP1061923B1 (fr) Agents utilises pour traiter la maladie d'alzheimer
Dedeoglu et al. Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis
Karr et al. Cu (II) binding to monomeric, oligomeric, and fibrillar forms of the Alzheimer’s disease amyloid-β peptide
US10113032B2 (en) Amine functional polyamides
US8680077B2 (en) Prochelators useful for inhibiting metal-associated toxicity
AU748768B2 (en) Identification of agents for use in the treatment of Alzheimer's disease
Dellinger et al. Inhibition of inflammatory arthritis using fullerene nanomaterials
US8273726B2 (en) Compositions for treating and/or preventing diseases characterized by the presence of metal ions
Kennedy et al. Cellular lipid metabolism is influenced by the coordination environment of copper
JP6312806B2 (ja) 抗菌薬耐性菌に対処するための組成物及び方法
TW470644B (en) Pharmaceutical compositions useful for inhibiting amyloid aggregation in a mammal
Nelson et al. Development of novel silyl cyanocinnamic acid derivatives as metabolic plasticity inhibitors for cancer treatment
US20020037908A1 (en) Methods and compositions for controlling protein assembly or aggregation
JP6122652B2 (ja) プロテアソーム活性化剤
Hernando-Gozalo et al. Study of the antimicrobial activity of cationic carbosilane dendrimers against clinical strains of multidrug-resistant bacteria and their biofilms
US20180221321A1 (en) Methods and products related to glutaminase inhibitors
EP1583765A2 (fr) Compositions destinees au traitement et/ou a la prevention de maladies caracterisees par la presence d'ions metalliques
ZA200504054B (en) Compositions for treating and/or preventing diseases characterized by the presence of metal ions
US20090203644A1 (en) Compositions for treating and/or preventing diseases characterized by the presence of metal ions
CN110121349B (zh) 铋(iii)化合物及其方法
US20240181023A1 (en) Functionalized biocatalytical compositions
US20220401402A1 (en) Compounds for preventing migration of cancer cells
WO2016023911A1 (fr) Utilisation de l'acide 1,3-propane disulfonique ou de sels de celui-ci pour empêcher l'apparition de l'amyloïdose chez certaines populations

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead